Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the FDA-approved drug nelfinavir (NFV) as an
oncologic agent for adenoid cystic cancers of the head and neck.
Specifically, subjects will be asked to take 1250 mg twice daily and follow-up with their
medical oncologist as clinically indicated while taking this medication.
Subjects would be evaluated for quality of life issues utilizing the EORTC QLQ-C30 2-page
questionnaire.
Subjects would also be evaluated clinically by the oncologist to determine if the NFV was
having an anti-neoplastic effect.
The study remains unfunded. Therefore, potential subjects must be willing to provide
self-travel to study site. This study requires a screening visit, initial study visit, and
monthly follow-up. Subjects are not reimbursed for time, travel, or physician costs.